AMERICAN TELEMEDICINE ASSOCIATION AND ATA ACTION APPLAUD DEA FOR OPENLY CONSIDERING A SPECIAL REGISTRATION PROCESS FOR REMOTE PRESCRIBING OF CONTROLLED SUBSTANCES

by ATA Action | Aug 5, 2023 | News, Press Releases

WASHINGTON, DC, AUGUST 4, 2023 – The American Telemedicine Association (ATA) and ATA Action issued the following statement in response to a notice posted earlier today by the Drug Enforcement Administration (DEA), indicating that the agency is openly considering a...

ATA AND ATA ACTION RESPOND TO CMS CY2024 PHYSICIAN FEE SCHEDULE PROPOSED RULE

by ATA Action | Jul 14, 2023 | News, Press Releases

WASHINGTON, DC, JULY 14, 2023 — The American Telemedicine Association (ATA) and ATA Action issued the following statement, in response to the Centers for Medicare & Medicaid Services (CMS) CY2024 Physician Fee Schedule (PFS) proposed policy changes for...

ATA AND ATA ACTION APPLAUD BROAD BIPARTISAN, BICAMERAL SUPPORT FOR REINTRODUCING THE MOST COMPREHENSIVE LEGISLATION ON TELEHEALTH

by ATA Action | Jun 16, 2023 | Press Releases

Connect for Health Act reintroduced with strong bipartisan support in the House and Senate to expand telehealth access WASHINGTON, DC, JUNE 15, 2023 — The American Telemedicine Association (ATA) and ATA Action issued the following statement, acknowledging the...

TELEHEALTH AS AN EXCEPTED BENEFIT CLEARS HOUSE EDUCATION AND WORKFORCE COMMITTEE, ENCOURAGING NEWS FOR MILLIONS OF AMERICAN WORKERS

by ATA Action | Jun 15, 2023 | Press Releases

Telehealth Benefit Expansion for Workers Act of 2023 would allow access to telehealth for all employees, including part-time, contracted and seasonal workers. Washington, DC, June 14, 2023 — The American Telemedicine Association (ATA) and ATA Action issued the...

ATA AND ATA ACTION RESPOND TO DEA’S EXTENSION OF COVID-19 TELEMEDICINE FLEXIBILITIES FOR REMOTE PRESCRIBING OF CONTROLLED SUBSTANCES

by ATA Action | May 4, 2023 | Press Releases

WASHINGTON, DC, MAY 4, 2023 – The American Telemedicine Association (ATA) and ATA Action issued the following statement in response to the Drug Enforcement Administration’s (DEA) extension of COVID-19 telemedicine flexibilities for the remote prescription of...